Altravax, Inc. Awarded $1.2 Million to Advance Dengue Vaccine and Hepatitis Therapeutic

Published: Jan 08, 2013

FARGO, N.D. & SUNNYVALE, Calif.--(BUSINESS WIRE)--Altravax, Inc. announced today that it has been awarded two Advanced Technology Small Business Innovation Research grants from the NIH’s National Institute of Allergy and Infectious Diseases for research on vaccines to prevent infection by dengue virus and to treat chronic hepatitis B. Each of these viruses is a global problem and the focus of Altravax’s two lead commercial programs.

Back to news